Solid splenic masses:: Evaluation with 18F-FDG PET/CT

被引:0
作者
Metser, U
Miller, E
Kessler, A
Lerman, H
Lievshitz, G
Oren, R
Even-Sapir, E
机构
[1] Tel Aviv Univ, Dept Nucl Med, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Univ, Dept Radiol, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, IL-64239 Tel Aviv, Israel
[3] Tel Aviv Univ, Dept Gastroenterol, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, IL-64239 Tel Aviv, Israel
关键词
hematology; oncology; FDG; PET/CT; spleen;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Our objective was to assess the role of F-18-FDG PET/CT in the evaluation of solid splenic masses in patients with a known malignancy and in incidentally found lesions in patients without known malignancy. Methods: Two groups of patients were assessed: (a) 68 patients with known malignancy and a focal lesion on PET or a solid mass on CT portions of the PET/CT study; and (b) 20 patients with solid splenic masses on conventional imaging without known malignancy. The standard of reference was histology (n = 16) or imaging and clinical follow-up (n = 72). The lesion size, the presence of a single versus multiple splenic lesions, and the intensity of 18F-FDG uptake expressed as a standardized uptake value (SUV) were recorded. The ratio of the SUV in the splenic lesion to the background normal splenic uptake was also calculated. These parameters were compared between benign and malignant lesions within each of the 2 groups of patients and between the 2 groups. Results: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of F-18-FDG PET/CT in differentiating benign from malignant solid splenic lesions in patients with and without malignant disease were 100%, 100%, 100%, and 100% versus 100%, 83%, 80%, and 100%, respectively. In patients with known malignant disease, an SUV threshold of 2.3 correctly differentiated benign from malignant lesions with the sensitivity, specificity, PPV, and NPV of 100%, 100%, 100%, and 100%, respectively. In patients without known malignant disease, false-positive results were due to granulomatous diseases (n - 2). Conclusion: F-18-FDG PET can reliably discriminate between benign and malignant solid splenic masses in patients with known F-18-FDG-avid malignancy. It also appears to have a high NPV in patients with solid splenic masses, without known malignant disease. F-18-FDG-avid splenic masses in patients without a known malignancy should be further evaluated as, in our series, 80% of them were malignant.
引用
收藏
页码:52 / 59
页数:8
相关论文
共 50 条
  • [41] 18F-FDG PET/CT in Bladder Cancer
    Tagliabue, Luca
    Russo, Giovanna
    Lucignani, Giovanni
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (12) : E522 - E524
  • [42] CT and 18F-FDG PET for Noninvasive Detection of Splenic Involvement in Patients with Malignant Lymphoma
    de Jong, Pim A.
    van Ufford, Henriette M. Quarles
    Baarslag, Henk-Jan
    de Haas, Marie J.
    Wittebol, Shulamiet H.
    Quekel, Lorentz G.
    de Klerk, John M.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 192 (03) : 745 - 753
  • [43] 18F-FDG PET/CT in Labrune Syndrome
    Cuzzocrea, Marco
    Florimonte, Luigia
    Scola, Elisa
    Benti, Riccardo
    Castellani, Massimo
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (10) : E439 - E440
  • [44] Diagnostic Value of 18F-FDG PET/CT in Comparison to Bone Scintigraphy, CT and 18F-FDG PET for the Detection of Bone Metastasis
    Liu, Ning-Bo
    Zhu, Lei
    Li, Ming-Huan
    Sun, Xiao-Rong
    Hu, Man
    Huo, Zong-Wei
    Xu, Wen-Gui
    Yu, Jin-Ming
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (06) : 3647 - 3652
  • [45] Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to 18F-FDG PET/CT
    Zheng, Dong
    Liu, Yi
    Liu, Jiajin
    Li, Ke
    Lin, Mu
    Schmidt, Holger
    Xu, Baixuan
    Tian, Jiahe
    CANCER IMAGING, 2020, 20 (01)
  • [46] Efficacy of conventional whole-body 18F-FDG PET/CT in the incidental findings of parotid masses
    Wang, Hui-Chun
    Zuo, Chuan-Tao
    Hua, Feng-Chun
    Huang, Zhe-Min
    Tan, Hai-Bo
    Zhao, Jun
    Guan, Yi-Hui
    ANNALS OF NUCLEAR MEDICINE, 2010, 24 (08) : 571 - 577
  • [47] The role of 18F-FDG PET/CT in the evaluation of pediatric transplant patients
    Yang, Jigang
    Zhuang, Hongming
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2015, 18 (02): : 136 - 139
  • [48] Performance of 18F-FDG PET/MR on TNM staging of pancreatic cancer compared with 18F-FDG PET/CT: A retrospective cohort study
    Zhang, H.
    Liu, S.
    Li, B.
    Hao, J.
    Zhang, Z.
    Shi, H.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2024, 48 (01): : 8 - 15
  • [49] 18F-FDG uptake in the normal appendix in adults: PET/CT evaluation
    Christopher Silman
    Shunro Matsumoto
    Asami Ono
    Maki Kiyonaga
    Kenichiro Otsuka
    Annals of Nuclear Medicine, 2019, 33 : 265 - 268
  • [50] 18F-FDG PET/CT Imaging of Tracheal Mucoepidermoid Carcinoma
    Jiang, Lei
    Huang, Yan
    Huang, Shanshan
    Li, Qiang
    Wang, Huoqiang
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (11) : 874 - 875